ThermoGenesis (THMO) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 12, 2020
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		6,360,991
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 5,719,000	$ 3,157,000
Restricted cash	1,000,000	1,000,000
Accounts receivable, net of allowance for doubtful accounts of $227,000 ($226,000 at December 31, 2019)	2,029,000	1,278,000
Inventories, net of reserves of $356,000 ($350,000 at December 31, 2019)	4,218,000	3,824,000
Prepaid expenses and other current assets	429,000	602,000
Total current assets	13,395,000	9,861,000
Equipment and leasehold improvements, net	1,904,000	2,028,000
Right-of-use operating lease assets, net	829,000	859,000
Goodwill	781,000	781,000
Intangible assets, net	1,434,000	1,467,000
Other assets	61,000	218,000
Total assets	18,404,000	15,214,000
Current liabilities:
Accounts payable	2,457,000	1,447,000
Accrued payroll and related expenses	406,000	288,000
Deferred revenue – short term	617,000	620,000
Interest payable – related party	443,000	1,869,000
Other current liabilities	2,558,000	2,461,000
Total current liabilities	6,481,000	6,685,000
Convertible promissory note – related party, less debt discount of $4,031,000 ($5,195,000 at December 31, 2019)	3,550,000	3,518,000
Convertible promissory note, plus debt premium of $22,000 ($46,000 at December 31, 2019)	209,000	413,000
Note payable	1,000,000	1,000,000
Operating lease obligations – long-term	726,000	761,000
Deferred revenue – long-term	1,814,000	1,901,000
Other noncurrent liabilities	19,000	20,000
Total liabilities	13,799,000	14,298,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 5,768,885 issued and outstanding (2,843,601 at December 31, 2019)	6,000	3,000
Additional paid in capital	245,704,000	237,313,000
Accumulated deficit	(241,534,000)	(236,932,000)
Accumulated other comprehensive loss	40,000	2,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	4,216,000	386,000
Noncontrolling interests	389,000	530,000
Total equity	4,605,000	916,000
Total liabilities and equity	$ 18,404,000	$ 15,214,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 227,000	$ 226,000
Inventories, reserves	356,000	350,000
Debt discount	$ 22,000	$ 46,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	5,768,885	2,843,601
Common stock, shares outstanding (in shares)	5,768,885	2,843,601
Convertible Promissory Note [Member]
Debt discount	$ 4,031,000	$ 5,195,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net revenues	$ 3,200,000	$ 2,962,000
Cost of revenues	1,708,000	1,704,000
Gross profit	1,492,000	1,258,000
Expenses:
Sales and marketing	444,000	341,000
Research and development	609,000	563,000
General and administrative	1,648,000	1,260,000
Total operating expenses	2,701,000	2,164,000
Loss from operations	(1,209,000)	(906,000)
Interest expense	(3,531,000)	(1,132,000)
Other income (expenses)	10,000	(9,000)
Loss on equity method investments	(13,000)
Total other expenses	(3,534,000)	(1,141,000)
Net loss	(4,743,000)	(2,047,000)
Loss attributable to noncontrolling interests	(141,000)	(176,000)
Net loss attributable to common stockholders	(4,602,000)	(1,871,000)
Net loss	(4,743,000)	(2,047,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	38,000	(4,000)
Comprehensive loss	(4,705,000)	(2,051,000)
Comprehensive loss attributable to noncontrolling interests	(141,000)	(176,000)
Comprehensive loss attributable to common stockholders	$ (4,564,000)	$ (1,875,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (1.11)	$ (0.76)
Weighted average common shares outstanding – basic and diluted (in shares)	4,135,644	2,461,415

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	Boyalife Investment Fund II, Inc. [Member]Common Stock [Member]	Boyalife Investment Fund II, Inc. [Member]Additional Paid-in Capital [Member]	Boyalife Investment Fund II, Inc. [Member]Retained Earnings [Member]	Boyalife Investment Fund II, Inc. [Member]AOCI Attributable to Parent [Member]	[1]	Boyalife Investment Fund II, Inc. [Member]Noncontrolling Interest [Member]	Boyalife Investment Fund II, Inc. [Member]	Registered Direct Offering [Member]Common Stock [Member]	Registered Direct Offering [Member]Additional Paid-in Capital [Member]	Registered Direct Offering [Member]Retained Earnings [Member]	Registered Direct Offering [Member]AOCI Attributable to Parent [Member]	[1]	Registered Direct Offering [Member]Noncontrolling Interest [Member]	Registered Direct Offering [Member]	At The Market Offering Agreement [Member]Common Stock [Member]	At The Market Offering Agreement [Member]Additional Paid-in Capital [Member]	At The Market Offering Agreement [Member]Retained Earnings [Member]	At The Market Offering Agreement [Member]AOCI Attributable to Parent [Member]	[1]	At The Market Offering Agreement [Member]Noncontrolling Interest [Member]	At The Market Offering Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	[1]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2018																						2,168,337
Balance at Dec. 31, 2018																						$ 2,000	$ 235,888,000	$ (227,435,000)	$ (13,000)		$ (1,711,000)	$ 6,731,000
Stock-based compensation expense																							81,000					81,000
Exercise of pre-funded warrants (in shares)																						50,000
Exercise of pre-funded warrants																							5,000					5,000
Discount due to beneficial conversion features																							1,513,000					1,513,000
Foreign currency translation gain (loss)																									(4,000)			(4,000)
Net loss																								(1,871,000)			(176,000)	(2,047,000)
Reorganization of subsidiary and related change in non-controlling interest																							(2,843,000)				2,843,000
Balance (in shares) at Mar. 31, 2019																						2,218,337
Balance at Mar. 31, 2019																						$ 2,000	234,644,000	(229,306,000)	(17,000)		956,000	6,279,000
Balance (in shares) at Dec. 31, 2019																						2,843,601
Balance at Dec. 31, 2019																						$ 3,000	237,313,000	(236,932,000)	2,000		530,000	916,000
Stock-based compensation expense																							67,000					67,000
Exercise of pre-funded warrants (in shares)																						100,000
Exercise of pre-funded warrants																							10,000					10,000
Exercise of warrants (in shares)																						7,866
Exercise of warrants																							47,000					47,000
Discount due to beneficial conversion features																							1,869,000					1,869,000
Conversion of note payable to common stock (in shares)	1,666,670																					100,000
Conversion of note payable to common stock	$ 2,000	$ 2,998,000					$ 3,000,000																180,000					180,000
Issuance of common stock (in shares)								1,000,002							50,746						50,746
Issuance of common stock								$ 1,000	$ 3,106,000					$ 3,107,000		$ 114,000					$ 114,000
Foreign currency translation gain (loss)																									38,000			38,000
Net loss																								(4,602,000)			(141,000)	(4,743,000)
Balance (in shares) at Mar. 31, 2020																						5,768,885
Balance at Mar. 31, 2020																						$ 6,000	$ 245,704,000	$ (241,534,000)	$ 40,000		$ 389,000	$ 4,605,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,743,000)	$ (2,047,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	199,000	206,000
Stock-based compensation expense	67,000	81,000
Amortization of debt discount/premium, net	522,000	586,000
Amortization of accelerated debt discount due to conversion	2,486,000
Reserve for excess and slow-moving inventories	6,000	86,000
Reserve for bad debt expense	1,000	6,000
Net change in operating assets and liabilities:
Accounts receivable	(752,000)	(485,000)
Inventories	(400,000)	99,000
Prepaid expenses and other assets	330,000	(90,000)
Accounts payable	1,035,000	38,000
Interest payable – related party	(1,426,000)	(1,053,000)
Accrued payroll and related expenses	118,000	(232,000)
Deferred revenue – short term	(3,000)	278,000
Other current liabilities	129,000	121,000
Long-term deferred revenue and other noncurrent liabilities	(110,000)	(30,000)
Net cash used in operating activities	(2,541,000)	(2,436,000)
Cash flows from investing activities:
Capital expenditures	(23,000)	(38,000)
Net cash used in investing activities:	(23,000)	(38,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party	1,869,000	1,513,000
Payment on finance lease obligations	(13,000)	(7,000)
Proceeds from issuance of common stock, net of expenses	3,220,000
Proceeds from the exercise of options, warrants and pre-funded warrants	57,000	5,000
Proceeds from note payable		800,000
Net cash provided by financing activities	5,133,000	2,311,000
Effects of foreign currency rate changes on cash and cash equivalents	(5,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	2,562,000	(163,000)
Cash, cash equivalents and restricted cash at beginning of period	4,157,000	3,400,000	$ 3,400,000
Cash, cash equivalents and restricted cash at end of period	6,719,000	3,237,000	$ 4,157,000
Supplemental disclosures of cash flow information:
Cash paid for interest	1,950,000	1,514,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	1,869,000	1,513,000
Right-to-use asset acquired under operating lease		966,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock	3,000,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock	$ 180,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Organization and Basis of Presentation ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), formerly known as Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company previously had two 2019, no no no two ® ® For Clinical Bio-Banking Applications: ● AXP ® ● BioArchive ® For Point-of-Care Applications: ● PXP ® For Large Scale Cell Processing and Biomanufacturing: ● X ® X ® X ® X ® X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress Bio, Inc. (“CARTXpress Bio”) is owned and developed through a subsidiary in which we own 80% On January 1, 2019, July 2017 20% third 20% 80% 100% In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, 20% $1,100,000. $2,843,000 On November 26, 2019 80% 20% 19% ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics. Reverse Stock Split On June 4, 2019, one 1 ten 10 350,000,000 not Liquidity and Going Concern The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 4 $10,000,000 March 31, 2020, $7,582,000 At March 31, 2020, $5,719,000 $6,914,000. March 31, 2020 $241,534,000. one may may The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not may Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. Non-controlling Interests The 20% not 80% Interim Reporting The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. three March 31, 2020 not may December 31, 2020. 10 December 31, 2019.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize revenues by product line: Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000 Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,267,000 $ 55,000 $ -- $ 1,322,000 BioArchive 599,000 415,000 -- 1,014,000 CAR-TXpress 307,000 -- -- 307,000 Manual Disposables 300,000 -- -- 300,000 Other 5,000 -- 14,000 19,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2020 $293,000. $617,000 $620,000 March 31, 2020 December 31, 2019, $1,814,000 $1,901,000 March 31, 2020 December 31, 2019, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three March 31, 2020, $71,000 $2,000,000 $1,834,000 $286,000 $1,548,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 807,000 $ 751,000 $ 324,000 $ 184,000 $ 38,000 $ 2,104,000 Clinical revenue 3,000 13,000 13,000 13,000 176,000 218,000 Exclusivity Fee 214,000 286,000 286,000 286,000 762,000 1,834,000 Total $ 1,024,000 $ 1,050,000 $ 623,000 $ 483,000 $ 976,000 $ 4,156,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 not 3 Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 224,445 246,500 March 31, 2020 2019 March 31: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 5,159,496 5,096,721 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,273,461 1,557,884 Stock options 287,849 290,933 Total 6,831,100 7,055,832 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3 . RELATED PARTY TRANSACTIONS HealthBanks Biotech (USA) Inc. On November 26, 2019 80% 20% 18.87% first 115% 2018 no $1,000,000 In December 2019, $3,000,000 600,000 $5.00 5.66% no 75.47% 18.87% 5.66% The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its’ lack of sufficient equity at inception. After the additional investment of $3,000,000, no $28,000, The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. 2 19 one thirty 30 In April 2020, 19. four 2 19 For the quarter ended March 31, 2020, $13,000 March 31, 2020 $0 March 31, 2020, $264,000. March 31, 2020, $2,561,000 $50,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, $10,000,000 March 6, 2022 ( February 2020, $1,869,000 $3,000,000 1,666,670 two March 31, 2020, $7,582,000. $2,486,000 The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% five The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no The Credit Agreement and Note were amended in April 2018. $16.10 two 2018, $1.80. It was concluded that the conversion option of the draw down in February 2020 $1,869,000 $1,869,000 March 31, 2020. $546,000 $586,000 three March 31, 2020 2019, $443,000 $461,000 March 31, 2020 2019, Distributor Agreement On August 21, 2017, ® ® ® ® ® The term of the agreement is for three two Revenues During the three March 31, 2020 2019, $0 $266,000,

Note 4 - Convertible Promissory

Note 4 - Convertible Promissory Note	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	4. CONVERTIBLE PROMISSORY NOTE On January 29, 2019, $800,000 “January 2019 six $1.80 2 90% $0.50 The January 2019 twenty-four 24% January 2019 eighteen 18 January 2019 January 2019 may On the date that is six January 2019 January 2019 January 2019 may January 2019 January 2019 4.99% 9.99% $800,000, May 30, 2019. The January 2019 January 2019 may January 2019 On July 23, 2019, No. 1 January 2019 January 2019 July 29, 2020 July 31, 2022. January 2019 January 2019 January 2019 10% January 2019 $840,000 December 31, 2019. $1,473,000 $556,000 December 31, 2019. $77,000 January 2019 December 31, 2019. The key assumptions used in the simulation model were: Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 % ( 1 For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 90% $0.50 During the three March 31, 2020, $180,000 100,000 $22,000 three March 31, 2020. On July 23, 2019, $1,000,000 “July 2019 six July 2019 $1.80 90% $0.50 July 2019 twenty-four 24% July 2019 three July 31, 2022. July 2019 not 2020 fourteen The July 2019 may six July 2019 may July 2019 July 2019

Note 5 - Leases

Note 5 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	5. LEASES The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2024. September 2023; September 2019 three Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating leases: March 31, 2020 Right-of-use operating lease assets, net $ 829,000 Current lease liability 127,000 Non-current lease liability 726,000 Weighted average remaining lease term 4.2 Discount rate 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2020 (remaining) $ 227,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,323,000 Less: imputed interest (494,000 ) Present value of operating lease liabilities $ 829,000 Statement of Cash Flows In January 2019, $966,000 $74,000 $71,000 March 31, 2020 2019, Operating Lease Costs Operating lease costs were $103,000 $103,000 March 31, 2020 2019, 30 Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases are and were not March 31, 2020 March 31, 2019.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6 . COMMITMENTS AND CONTINGENCIES Financial Covenants On March 17, 2020, #1 March 16, 2020 ( May 15, 2017 $2.0 $1.0 The Company was in compliance with this financial covenant as of March 31, 2020. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the three March 31, 2020 Balance at December 31, 2019 $ 277,000 Warranties issued during the period 30,000 Settlements made during the period (133,000 ) Changes in liability for pre-existing warranties during the period (31,000 ) Balance at March 31, 2020 $ 143,000 Contingen cies and Restricted Cash In fiscal 2016, May 4, 2017, $1,000,000 August 2016. October 2017, $1,000,000 February 2020 $1,000,000. $1,400,000 December 31, 2019. $1,000,000 $400,000 $1,000,000 no April 2020, May 1, 2020 $480,000, $369,000 $111,000 not $1,000,000 In the normal course of operations, the Company may March 31, 2020, may not

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7 . STOCKHOLDERS’ EQUITY Common Stock On March 25, 2020, three 1,000,002 $3.50 $3.5 $393,000 3 No. 333 235509 December 13, 2019 January 3, 2020, March 27, 2020. March 27, 2020. 30 twelve 12 On December 13, 2019, may $4.4 3 No. 333 235509 may 415 may not August 9, 2022. 3% March 31, 2020, 50,746 $280,000 $5.44 $114,000 $167,000. March 25, 2020, Stock Based Compensation The Company recorded stock-based compensation of $67,000 $81,000 three March 31, 2020 2019, Three Months Ended March 31, 2020 2019 Sales and marketing $ 13,000 $ 12,000 Research and development 15,000 15,000 General and administrative 39,000 54,000 $ 67,000 $ 81,000 The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Forfeited (3,958 ) $ 3.74 Outstanding at March 31, 2020 287,849 $ 14.10 8.06 $ 101,074 Vested and expected to vest at March 31, 2020 226,960 $ 15.70 7.9 $ 75,434 Exercisable at March 31, 2020 143,479 $ 20.20 7.61 $ 40,430 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no three March 31, 2020. Warrants A summary of warrant activity for the three March 31, 2020 Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (107,866 ) $ .53 Outstanding at March 31, 2020 1,608,200 $ 26.89 Exercisable at March 31, 2020 1,538,347 $ 24.47

Note 8 - Subsequent Events

Note 8 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	8 . S UBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no On April 21, 2020, $646,000 two 1.00% first six may may On April 28, 2020, $2,418,000 3, $10,000,000 $580,000 April 28, 2020. 2 19 3, Between April 7, 2020 – May 12, 2020, 263,216 $6 May 2018. $1,600,000 May 12, 2020, 626,821 $6 May 2018 In April 2020, $188,000 January 2019 104,445 224,445 April 2019 no April 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020, In August 2018, 2018 13, Fair Value Measurement (“Topic 820” not In June 2016, ASU 2016 13, “ Financial Instruments - Credit Losses ( “ Topic 326 ” ). ” 2016 13 December 15, 2022, not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606: The following tables summarize revenues by product line: Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000 Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,267,000 $ 55,000 $ -- $ 1,322,000 BioArchive 599,000 415,000 -- 1,014,000 CAR-TXpress 307,000 -- -- 307,000 Manual Disposables 300,000 -- -- 300,000 Other 5,000 -- 14,000 19,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2020 $293,000. $617,000 $620,000 March 31, 2020 December 31, 2019, $1,814,000 $1,901,000 March 31, 2020 December 31, 2019, Exclusivity Fee On August 30, 2019, five two X ® $2,000,000 The Company performed an evaluation of the revenue recognition of the $2,000,000 606. $2,000,000 one two five seven seven three March 31, 2020, $71,000 $2,000,000 $1,834,000 $286,000 $1,548,000 Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 807,000 $ 751,000 $ 324,000 $ 184,000 $ 38,000 $ 2,104,000 Clinical revenue 3,000 13,000 13,000 13,000 176,000 218,000 Exclusivity Fee 214,000 286,000 286,000 286,000 762,000 1,834,000 Total $ 1,024,000 $ 1,050,000 $ 623,000 $ 483,000 $ 976,000 $ 4,156,000 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Level 2: Level 3: no The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 not 3
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no 224,445 246,500 March 31, 2020 2019 March 31: 2020 2019 Common stock equivalents of convertible promissory note and accrued interest 5,159,496 5,096,721 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,273,461 1,557,884 Stock options 287,849 290,933 Total 6,831,100 7,055,832 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,208,000 $ 24,000 $ -- $ 2,232,000 BioArchive 164,000 332,000 -- 496,000 CAR-TXpress 152,000 12,000 71,000 235,000 Manual Disposables 203,000 -- -- 203,000 Other 14,000 -- 20,000 34,000 Total $ 2,741,000 $ 368,000 $ 91,000 $ 3,200,000 Three Months Ended March 31, 2019 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,267,000 $ 55,000 $ -- $ 1,322,000 BioArchive 599,000 415,000 -- 1,014,000 CAR-TXpress 307,000 -- -- 307,000 Manual Disposables 300,000 -- -- 300,000 Other 5,000 -- 14,000 19,000 Total $ 2,478,000 $ 470,000 $ 14,000 $ 2,962,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2020 2021 2022 2023 2024 and beyond Total Service revenue $ 807,000 $ 751,000 $ 324,000 $ 184,000 $ 38,000 $ 2,104,000 Clinical revenue 3,000 13,000 13,000 13,000 176,000 218,000 Exclusivity Fee 214,000 286,000 286,000 286,000 762,000 1,834,000 Total $ 1,024,000 $ 1,050,000 $ 623,000 $ 483,000 $ 976,000 $ 4,156,000
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2020 2019 Common stock equivalents of convertible promissory note and accrued interest 5,159,496 5,096,721 Vested Series A warrants 40,441 40,441 Unvested Series A warrants (1) 69,853 69,853 Warrants – other 1,273,461 1,557,884 Stock options 287,849 290,933 Total 6,831,100 7,055,832

Note 4 - Convertible Promisso_2

Note 4 - Convertible Promissory Note (Tables)	3 Months Ended
	Mar. 31, 2020
Convertible Debt [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Stock price at date of issuance $ 3.05 Exercise price (1) $ 1.80 Risk-free interest rate 1.8 % Expected dividend yield -- Expected term (in years) 3.02 Expected volatility 93 %

Note 5 - Leases (Tables)

Note 5 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	March 31, 2020 Right-of-use operating lease assets, net $ 829,000 Current lease liability 127,000 Non-current lease liability 726,000 Weighted average remaining lease term 4.2 Discount rate 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 (remaining) $ 227,000 2021 310,000 2022 319,000 2023 328,000 2024 139,000 Thereafter -- Total lease payments $ 1,323,000 Less: imputed interest (494,000 ) Present value of operating lease liabilities $ 829,000

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2019 $ 277,000 Warranties issued during the period 30,000 Settlements made during the period (133,000 ) Changes in liability for pre-existing warranties during the period (31,000 ) Balance at March 31, 2020 $ 143,000

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2020 2019 Sales and marketing $ 13,000 $ 12,000 Research and development 15,000 15,000 General and administrative 39,000 54,000 $ 67,000 $ 81,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2019 291,807 $ 13.96 Forfeited (3,958 ) $ 3.74 Outstanding at March 31, 2020 287,849 $ 14.10 8.06 $ 101,074 Vested and expected to vest at March 31, 2020 226,960 $ 15.70 7.9 $ 75,434 Exercisable at March 31, 2020 143,479 $ 20.20 7.61 $ 40,430
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Balance at December 31, 2019 1,716,066 $ 25.23 Warrants expired -- -- Warrants exercised (107,866 ) $ .53 Outstanding at March 31, 2020 1,608,200 $ 26.89 Exercisable at March 31, 2020 1,538,347 $ 24.47

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual)	Jun. 04, 2019	Jan. 01, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)shares	Mar. 31, 2020USD ($)shares	Nov. 26, 2019USD ($)	Jun. 30, 2019shares	Mar. 31, 2017USD ($)
Number of Reportable Segments				2
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance				$ 530,000	$ 389,000
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized (in shares) | shares				350,000,000	350,000,000		350,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance				$ 3,157,000	$ 5,719,000
Working Capital					6,914,000
Retained Earnings (Accumulated Deficit), Ending Balance				$ (236,932,000)	(241,534,000)
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000			$ 10,000,000
Long-term Line of Credit, Total					$ 7,582,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage				18.87%	18.87%	20.00%
Line of Credit Facility, Maximum Borrowing Capacity						$ 1,000,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.47%		80.00%
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest		$ 2,843,000	$ 2,843,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Parent		80.00%		80.00%	80.00%
Minority Interest Acquired Through Exchange		20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance		$ 1,100,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					20.00%
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent		100.00%
Ownership in Subsidiary Exchanged		20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance		$ (1,711,000)

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Aug. 30, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Deferred Revenue, Total		$ 293,000
Deferred Revenue, Current, Total		617,000		$ 620,000
Deferred Revenue, Noncurrent, Total		$ 1,814,000		$ 1,901,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		6,831,100	7,055,832
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		224,445	246,500
Exclusivity Fee [Member]
Deferred Revenue, Total		$ 1,834,000
Deferred Revenue, Current, Total		286,000
Deferred Revenue, Noncurrent, Total		1,548,000
Contract with Customer, Liability, Revenue Recognized		$ 71,000
Supply Agreement [Member]
Supply Agreement, Term (Year)	5 years	7 years
Supply Agreement, Renewal Term (Year)	2 years	2 years
Contract with Customer, Liability, Total	$ 2,000,000
Proceeds from Customers		$ 2,000,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net revenues	$ 3,200,000	$ 2,962,000
Device [Member] | AXP [Member]
Net revenues	2,232,000	1,322,000
Device [Member] | BioArchive [Member]
Net revenues	496,000	1,014,000
Device [Member] | CAR-TXpress [Member]
Net revenues	235,000	307,000
Device [Member] | Manual Disposables [Member]
Net revenues	203,000	300,000
Device [Member] | Other Subsegments [Member]
Net revenues	34,000	19,000
Device Revenue [Member]
Net revenues	2,741,000	2,478,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	2,208,000	1,267,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	164,000	599,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	152,000	307,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	203,000	300,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	14,000	5,000
Service [Member]
Net revenues	368,000	470,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	24,000	55,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	332,000	415,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	12,000
Service [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Service [Member] | Device [Member] | Other Subsegments [Member]
Net revenues
Other [Member]
Net revenues	91,000	14,000
Other [Member] | Device [Member] | AXP [Member]
Net revenues
Other [Member] | Device [Member] | BioArchive [Member]
Net revenues
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000
Other [Member] | Device [Member] | Manual Disposables [Member]
Net revenues
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	$ 20,000	$ 14,000

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Mar. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,156,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,104,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	218,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,834,000

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Mar. 31, 2020USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,156,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,024,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,050,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 623,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 483,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 976,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,104,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 807,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 751,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 324,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 184,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 38,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 218,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 3,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 176,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,834,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 214,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 762,000

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Anti-dilutive securities (in shares)		6,831,100	7,055,832
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		5,159,496	5,096,721
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		40,441	40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	69,853	69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		1,273,461	1,557,884
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		287,849	290,933
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Related Party Transa_2

Note 3 - Related Party Transactions (Details Textual) - USD ($)	Feb. 29, 2020	Aug. 21, 2017	Feb. 29, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Equity Method Investment, Other than Temporary Impairment					$ (13,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(4,743,000)	(2,047,000)
Assets, Current, Total				$ 9,861,000	13,395,000
Liabilities, Current, Total				6,685,000	6,481,000
Amortization of Accelerated Debt Discount Due to Conversion					2,486,000
Amortization of Debt Discount (Premium)					522,000	586,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			1,666,670
Boyalife Investment Fund II, Inc. [Member] | Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000					$ 10,000,000
Proceeds from Long-term Lines of Credit			$ 1,869,000
Long-term Line of Credit, Total					7,582,000
Amortization of Accelerated Debt Discount Due to Conversion					$ 2,486,000
Debt Instrument, Interest Rate, Stated Percentage					22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 1,869,000
Debt Instrument, Unamortized Discount, Total					$ 1,869,000
Amortization of Debt Discount (Premium)					546,000	586,000
Interest Payable					443,000	461,000
Boyalife W.S.N. [Member]
Distributor Agreement Term (Year)		3 years
Distributor Agreement, Renewal Term (Year)		2 years
Accounts Receivable, Related Parties					$ 0	$ 266,000
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock				$ 3,000,000
ImmuneCyte [Member] | Common Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares)				600,000
Shares Issued, Price Per Share (in dollars per share)				$ 5
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage				18.87%	18.87%		20.00%
Joint Venture Purchase, Percent of Company's Cost							115.00%
Line of Credit Facility, Maximum Borrowing Capacity							$ 1,000,000
Equity Method Investment, Aggregate Cost					$ 0		$ 28,000
Equity Method Investment, Other than Temporary Impairment					(13,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(264,000)
Assets, Current, Total					2,561,000
Liabilities, Current, Total					$ 50,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.47%			80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage				5.66%

Note 4 - Convertible Promisso_3

Note 4 - Convertible Promissory Note (Details Textual) - USD ($)	Jul. 23, 2019	Jan. 29, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	May 30, 2019
Amortization of Debt Discount (Premium)			$ 522,000	$ 586,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 180,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)			100,000
Convertible Debt [Member] | Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Debt Instrument, Term (Month)		1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers		4.99%
Debt Instrument, Convertible, Second customary conversion blockers		9.99%
Debt Instrument, Unamortized Discount, Total						$ 800,000
Convertible Debt [Member] | Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount		$ 800,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80
Convertible Debt [Member] | Notes [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.50
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Unamortized Discount, Total					$ 556,000
Gain (Loss) on Extinguishment of Debt, Total					840,000
Long-term Debt, Fair Value	$ 1,473,000
Amortization of Debt Discount (Premium)					$ 77,000
Interest Income (Expense), Net, Total			$ 22,000
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | January 2019 Notes, Amendment No. 1 [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50

Note 4 - Convertible Promisso_4

Note 4 - Convertible Promissory Note - Assumptions (Details) - Convertible Debt [Member]	Jul. 23, 2019
Measurement Input, Share Price [Member]
Long-term Debt, Measurement Input	3.05
Measurement Input, Exercise Price [Member]
Long-term Debt, Measurement Input	1.8	[1]
Measurement Input, Risk Free Interest Rate [Member]
Long-term Debt, Measurement Input	0.018
Measurement Input, Expected Dividend Rate [Member]
Long-term Debt, Measurement Input
Measurement Input, Expected Term [Member]
Long-term Debt, Measurement Input	3.02
Measurement Input, Price Volatility [Member]
Long-term Debt, Measurement Input	0.93
[1]	For the exercise price, the model inputs also accounted for the fair value protection under the Amended Note, which allows for the holder to convert at the lower of $1.80 share or 90% of the listed price of the stock on the day of conversion, whichever is lower (subject to a floor of $0.50).

Note 5 - Leases (Details Textua

Note 5 - Leases (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 829,000		$ 859,000
Operating Lease, Payments	74,000	$ 71,000
Operating Lease, Cost	$ 103,000	$ 103,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000

Note 5 - Leases - Lease Informa

Note 5 - Leases - Lease Information (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Right-of-use operating lease assets, net	$ 829,000	$ 859,000
Non-current lease liability	$ 726,000	$ 761,000
Weighted average remaining lease term (Year)	4 years 73 days
Discount rate	22.00%
Current Liabilities [Member]
Current lease liability	$ 127,000

Note 5 - Leases - Maturities of

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Mar. 31, 2020USD ($)
2020 (remaining)	$ 227,000
2021	310,000
2022	319,000
2023	328,000
2024	139,000
Thereafter
Total lease payments	1,323,000
Less: imputed interest	(494,000)
Present value of operating lease liabilities	$ 829,000

Note 6 - Commitments and Cont_3

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	May 01, 2020	May 04, 2017	Feb. 29, 2020	Oct. 31, 2017	Mar. 31, 2020	Mar. 17, 2020	Dec. 31, 2019
Short Term Investment Minimum						$ 1,000,000	$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value		$ 1,000,000
Loss Contingency, Negotiation Condition Bond				$ 1,000,000
Loss Contingency, Damages Awarded, Value			$ 1,000,000
Gain (Loss) Related to Litigation Settlement, Total			(1,400,000)
Litigation Settlement, Expense			1,000,000
Litigation Settlement Interest			$ 400,000
Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member] | Subsequent Event [Member]
Litigation Settlement, Expense	$ 111,000
Litigation Settlement Interest	369,000
Loss Contingency, Damages Awarded, Value	$ 480,000
Minimum [Member]
Period Of Warranty On Products (Year)					1 year
Maximum [Member]
Period Of Warranty On Products (Year)					2 years

Note 6 - Commitments and Cont_4

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Balance	$ 277,000
Warranties issued during the period	30,000
Settlements made during the period	(133,000)
Changes in liability for pre-existing warranties during the period	(31,000)
Balance	$ 143,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Mar. 27, 2020	Dec. 13, 2019	Mar. 31, 2020	Mar. 31, 2019
Proceeds from Issuance of Common Stock, Net			$ 3,220,000
Share-based Payment Arrangement, Expense			$ 67,000	$ 81,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			0
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,000,002
Shares Issued, Price Per Share (in dollars per share)	$ 3.50
Proceeds from Issuance of Common Stock	$ 3,500,000
Payments of Stock Issuance Costs	$ 393,000
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			50,746
Proceeds from Issuance of Common Stock			$ 280,000
Payments of Stock Issuance Costs			$ 167,000
Maximum Offering Price for Issuance of Common Stock		$ 4,400,000
Commission as Percentage of Gross Proceeds		3.00%
Shares Issued, Average Price Per Share (in dollars per share)			$ 5.44
Proceeds from Issuance of Common Stock, Net			$ 114,000

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation	$ 67,000	$ 81,000
Selling and Marketing Expense [Member]
Stock-based compensation	13,000	12,000
Research and Development Expense [Member]
Stock-based compensation	15,000	15,000
General and Administrative Expense [Member]
Stock-based compensation	$ 39,000	$ 54,000

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	291,807
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.96
Forfeited, options (in shares) | shares	(3,958)
Forfeited, weighted average exercise price, options (in dollars per share) | $ / shares	$ 3.74
Outstanding, options (in shares) | shares	287,849
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 14.10
Outstanding, weighted average remaining contractual life, options (Year)	8 years 21 days
Outstanding, aggregate intrinsic value, options | $	$ 101,074
Vested and Expected to Vest, options (in shares) | shares	226,960
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 15.70
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	7 years 328 days
Vested and Expected to Vest, aggregate intrinsic value, options | $	$ 75,434
Exercisable, options (in shares) | shares	143,479
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 20.20
Exercisable, weighted average remaining contractual life, options (Year)	7 years 222 days
Exercisable, aggregate intrinsic value, options | $	$ 40,430

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Outstanding (in shares) | shares	1,716,066
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 25.23
Warrants expired (in shares) | shares
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares
Warrants exercised (in shares) | shares	(107,866)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.53
Outstanding (in shares) | shares	1,608,200
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 26.89
Exercisable (in shares) | shares	1,538,347
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 24.47

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)	Apr. 28, 2020	Apr. 21, 2020	May 12, 2020	Apr. 30, 2020	Feb. 29, 2020	Mar. 31, 2020	Mar. 31, 2019	May 14, 2020	Dec. 31, 2019
Class of Warrant or Right, Exercised During Period (in shares)						107,866
Proceeds from Warrant Exercises						$ 57,000	$ 5,000
Class of Warrant or Right, Outstanding (in shares)						1,608,200			1,716,066
Revolving Credit Facility [Member] | Boyalife Investment Fund II, Inc. [Member]
Proceeds from Long-term Lines of Credit					$ 1,869,000
Long-term Line of Credit, Total						$ 7,582,000
Interest Payable						$ 443,000	$ 461,000
Subsequent Event [Member]
Proceeds from Paycheck Protection Program Under CARES Act		$ 646,000
Subsequent Event [Member] | Conversion of Convertible Promissory Note into Common Stock [Member]
Debt Conversion, Original Debt, Amount				$ 188,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)				104,445
Subsequent Event [Member] | Warrants Issused in Private Placement [Member]
Class of Warrant or Right, Exercised During Period (in shares)			263,216
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 6
Proceeds from Warrant Exercises			$ 1,600,000
Class of Warrant or Right, Outstanding (in shares)			626,821
Subsequent Event [Member] | April 2019 Pre-funded Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)				224,445
Class of Warrant or Right, Outstanding (in shares)								0
Subsequent Event [Member] | Revolving Credit Facility [Member] | Boyalife Investment Fund II, Inc. [Member]
Proceeds from Long-term Lines of Credit	$ 2,418,000
Long-term Line of Credit, Total	10,000,000
Interest Payable	$ 580,000